STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…

≈